BioTuesdays

Tag - Supernus Pharmaceuticals

Supernus Pharmaceuticals Logo

Stifel cuts Supernus Pharma to hold; PT to $23 from $55

Stifel downgraded Supernus Pharmaceuticals (NASDAQ:SUPN) to “hold” from “buy” and slashed its price target to $23 from $55 after a Phase 3 miss with drug candidate, SPN-810, for the treatment of impulsive aggression in...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.